Anti-Mouse MAdCAM-1 (MECA-89) – Purified in vivo PLATINUMTM Functional Grade
Anti-Mouse MAdCAM-1 (MECA-89) – Purified in vivo PLATINUMTM Functional Grade
Product No.: M1421
Clone MECA-89 Target MADCAM-1 Formats AvailableView All Product Type Hybridoma Monoclonal Antibody Alternate Names Mucosal addressin cell adhesion molecule-1 Isotype Rat IgG2a κ Applications B , FA , FC , IF , IHC , IP , WB |
Antibody DetailsProduct DetailsReactive Species Mouse Host Species Rat Recommended Isotype Controls Recommended Isotype Controls Recommended Dilution Buffer Immunogen Mouse mesenteric and peripheral lymph node cells Product Concentration ≥ 5.0 mg/ml Endotoxin Level ≤ 1.0 EU/mg as determined by the LAL method Purity ≥95% by SDS Page ⋅ ≥95% monomer by analytical SEC Formulation This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. State of Matter Liquid Product Preparation Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. Pathogen Testing To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s Purified Functional PLATINUM<sup>TM</sup> antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile. Storage and Handling Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles. Regulatory Status Research Use Only Country of Origin USA Shipping 2 - 8°C Wet Ice Additional Applications Reported In Literature ? FA IHC IF IP WB FC B Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity MECA-89 activity is directed against mouse MAdCAM-1. Background MAdCAM-1 is a cell adhesion leukocyte receptor expressed by mucosal venules that helps direct lymphocyte traffic into mucosal tissues and regulates the passage and retention of leukocytes1, 2. MAdCAM-1 binds integrin receptor α4β7 and L-selectin2, 3, 4. Two alternatively spliced isoforms of MAdCAM-1 exist5, both of which are capable of binding α4β72. MECA-89 was generated by immunizing Wistar rats with endothelial cells isolated from BALB/c mesenteric and peripheral lymph nodes 6. Immunohistological screening of hybridomas yielded two mAbs, MECA-367 and MECA-89, that stain high endothelial venules (HEVs) in mucosal lymphoid organs and Peyer’s patches, but not peripheral lymph nodes (axillary, brachial, popliteal, and inguinal). Immunofluorescence staining of high endothelial cells shows that both MECA-367 and MECA-89 react with antigens on the cell surface. The epitopes for MECA-367 and MECA-89 are distinct. MECA-367 recognizes the N-terminal immunoglobulin domain of MAdCAM-l, and MECA-89 recognizes the second immunoglobulin domain 4,5. MECA-89 reacts with the same vessels as MECA-367 and binds to isolated MECA-367 antigen; however, unlike MECA-367 it has no effect on lymphocyte binding 6. Additionally, MECA-89 has no effect on MAdCAM-1 binding to α4β7 in vitro 7, but L-selectin dependent adhesion is lost in the presence of MECA-89 4. Additionally, MECA-89 has no significant effect on activated cells, but all interactions are inhibited following subsequent injection of anti-α4 Fab fragments 4. In vivo, MECA-89 inhibits L-selectin-dependent rolling but not direct α4β7-dependent attachment of Mn2+ activated lymphocytes. Antigen Distribution MAdCAM-1 is a cell surface glycoprotein selectively expressed on high endothelial venules of mucosal lymphoid organs and Peyer’s patches as well as lamina propria venules. Ligand/Receptor Integrin a4ß7, CD62L NCBI Gene Bank ID UniProt.org Research Area Cell Adhesion . Cell Biology . Immunology Leinco Antibody AdvisorPowered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments. Clone MECA-89 is commonly used in vivo in mice to neutralize or block MAdCAM-1 (Mucosal Addressin Cell Adhesion Molecule-1) function, which plays an essential role in immune cell trafficking, particularly in the context of gut and mucosal immunity. Researchers typically use MECA-89 in mouse models to study mechanisms of leukocyte homing, inflammation, and diseases affecting mucosal tissues. Key in vivo applications of MECA-89 in mice include:
Summary Table of Common In Vivo Applications of MECA-89 in Mice
MECA-89 is primarily regarded as a blocking antibody for MAdCAM-1, making it a foundational tool for dissecting immune cell migration and mucosal immune responses in mouse models. Commonly used antibodies or proteins in combination with MECA-89 (anti-MAdCAM-1) in the literature include integrins (especially α4β7 integrin), other addressins, and standard immune markers such as CD45, B220, and CD40. Key reagents and markers commonly used alongside MECA-89:
These marker panels are often used in immune tissue studies, notably of mucosal lymphoid organs, Peyer's patches, or lymph node HEVs, to characterize both vascular structure and immune cell populations present in situ. Summary table:
These combinations allow delineation of specific endothelial and leukocyte populations, study of lymphocyte homing, and functional differentiation within lymphoid tissues. Key findings from scientific literature citing clone MECA-89 focus on two distinct research areas, due to ambiguity in the naming: immunological studies with the anti-MAdCAM-1 antibody (clone MECA-89) and studies on the mecA gene in Staphylococcus aureus. However, in antibody and cell biology literature, MECA-89 specifically refers to a rat monoclonal antibody targeting mouse MAdCAM-1, and this is the most likely context for your query. Key findings from citations of clone MECA-89 (anti-MAdCAM-1 antibody) include:
Essential context:
Alternative context (less likely but present in search results):
The most relevant and authoritative findings pertain to the immunological use of clone MECA-89 as an anti-MAdCAM-1 monoclonal antibody in mouse models to study lymphocyte trafficking and mucosal vascular biology. Dosing Regimens of Clone MECA-89 Across Different Mouse ModelsOverview The dosing regimens for the anti-MAdCAM-1 antibody clone MECA-89 in mouse models are not standardized and are determined primarily by the specific disease context, pharmacokinetic (PK) parameters, and intended pharmacodynamic (PD) effects. However, direct, detailed information on MECA-89 dosing schedules in recent literature is sparse, and regimens appear to be highly model-dependent, reflecting differences in experimental goals and disease models. Factors Influencing Dosing
Comparison to Related AntibodiesWhile specific MECA-89 regimens are not detailed in the provided literature, data for related anti-MAdCAM-1 clones (e.g., MECA-367) show that typical administration is via intravenous injection at single doses, but exact amounts and schedules are not specified and likely vary by study. This variability is consistent with the broader trend for therapeutic antibodies in mice, where dosing is tailored to the experimental model and endpoints. General Principles in Mouse Antibody Dosing
Summary Table: Key Determinants of MECA-89 Dosing in Mouse Models
ConclusionDosing regimens for clone MECA-89 in mouse models are not fixed and must be optimized for each specific experimental context, taking into account disease model, PK/PD characteristics, and the desired biological outcome. There is no universal dosing schedule, and researchers are advised to conduct pilot PK/PD studies to establish appropriate regimens for their particular mouse model and research question. References & Citations1. https://www.uniprot.org/uniprotkb/Q61826/entry
2. Schiffer SG, Day E, Latanision SM, et al. Biochem Biophys Res Commun. 216(1):170-176. 1995. 3. Berlin C, Berg EL, Briskin MJ, et al. Cell. 74(1):185-195. 1993. 4. Bargatze RF, Jutila MA, Butcher EC. Immunity. 3(1):99-108. 1995. 5. Briskin MJ, McEvoy LM, Butcher EC. Nature. 363(6428):461-464. 1993. 6. Streeter PR, Berg EL, Rouse BT, et al. Nature. 331(6151):41-46. 1988. 7. Nakache M, Berg EL, Streeter PR, et al. Nature. 337(6203):179-181. 1989. Technical ProtocolsCertificate of Analysis |
Related Products
Formats Available
Prod No. | Description |
---|---|
M1422 | |
M1425 | |
M1423 | |
M1424 | |
M1420 | |
M1421 |
